{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:49:24Z","timestamp":1790902164894,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T00:00:00Z","timestamp":1133222400000},"content-version":"vor","delay-in-days":6482,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1988,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anticentromere antibodies (ACA) and anti\u2013topoisomerase I (anti\u2013topo I) were assayed in serum samples from 355 patients: 89 with proximal scleroderma; 54 with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), without proximal scleroderma; 154 with primary and secondary Raynaud's disease; and 58 with other rheumatic diseases, without Raynaud's disease. Sera from healthy control subjects were also assayed. Using immunoblotting techniques, anti\u2010topo I was detected in 28% of the patients with proximal scleroderma; using immunodiffusion techniques, this antibody was found in only 20% of the same group of patients. Anti\u2013topo I and ACA were found primarily in patients with scleroderma, CREST syndrome, and Raynaud's phenomenon. ACA identified patients with less severe disease, whereas anti\u2013topo I identified patients with skin and cardiac involvement and patients with malignancies.<\/jats:p>","DOI":"10.1002\/art.1780310309","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T22:13:48Z","timestamp":1171491228000},"page":"378-385","source":"Crossref","is-referenced-by-count":176,"title":["Clinical associations of anticentromere antibodies and antibodies to topoisomerase i. a study of 355 patients"],"prefix":"10.1002","volume":"31","author":[{"given":"E. S.","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. C.","family":"Earnshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010L.","family":"SeneAcal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bordwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. F.","family":"Rothfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,29]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90462-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230602"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.4.382"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780260101"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541227"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archderm.1983.01650310022004","article-title":"Anticentromere and anticentriole antibodies in the scleroderma spectrum","volume":"119","author":"Tuffanelli DL","year":"1983","journal-title":"Arch Dermatol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.1.23"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270202"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270201"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.6.819"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.121.3.339"},{"key":"e_1_2_1_13_2","first-page":"205","article-title":"Antinuclear antibodies in progressive systemic sclerosis","volume":"3","author":"Ribaldi P","year":"1985","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_14_2","first-page":"911","article-title":"Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis","volume":"13","author":"Giordano M","year":"1986","journal-title":"J Rheumatol"},{"key":"e_1_2_1_15_2","first-page":"227","article-title":"Association of anticentromere and anti\u2010Scl\u201070 antibodies in scleroderma: report of two cases","volume":"16","author":"Ruffatti A","year":"1985","journal-title":"J Clin Lab Immunol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00328227"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112320"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3003910"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111767"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00286991"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.14.5145"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_1_24_2","first-page":"175","article-title":"1958 revision of diagnostic criteria for rheumatoid arthritis","volume":"9","author":"Ropes MW","year":"1958","journal-title":"Bull Rheum Dis"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197707000-00001"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1976.tb00855.x"},{"key":"e_1_2_1_27_2","first-page":"1041","article-title":"Systemic sclerosis and malignancy: are they related?","volume":"12","author":"Medsger TA","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_1_28_2","first-page":"1136","article-title":"Incidence of lung cancer in systemic sclerosis","volume":"12","author":"Peters\u2010Golden M","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(85)90022-5"},{"issue":"4","key":"e_1_2_1_30_2","first-page":"S53","article-title":"Prognostic significance of anticentromere antibodies and antibodies to topoisomerase I in Raynaud's disease (abstract)","volume":"29","author":"Weiner E","year":"1986","journal-title":"Arthritis Rheum (suppl)"},{"key":"e_1_2_1_31_2","first-page":"43","article-title":"Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis","volume":"48","author":"Bernstein RM","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_32_2","first-page":"994","volume-title":"Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis, Arthritis and Allied Conditions. Tenth edition","author":"Medsger TA","year":"1985"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780310309","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780310309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T04:47:07Z","timestamp":1694926027000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780310309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1988,3]]}},"alternative-id":["10.1002\/art.1780310309"],"URL":"https:\/\/doi.org\/10.1002\/art.1780310309","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,3]]}}}